NCT03499808 2025-09-09S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary AmyloidosisSWOG Cancer Research NetworkPhase 2 Completed43 enrolled 23 charts
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled